CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,953,260
- in 5 filings, $6.0M under 10b5-1 plans
Net −$5,953,260. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-08-11 | KURIYEL RALF Senior VP, R&D | Option exercise | +646 | $86.10 | $56K | 24,110 |
| 2022-08-11 | KURIYEL RALF Senior VP, R&D | Sale | −800 | $255.20 | $204K | 23,310 |
| 2022-08-11 | KURIYEL RALF Senior VP, R&D | Sale | −4,040 | $254.14 | $1.0M | 19,270 |
| 2022-08-11 | KURIYEL RALF Senior VP, R&D | Option exercise · Stock Option (Right to Buy) | +2,000 | 0 | ||
| 2022-08-11 | KURIYEL RALF Senior VP, R&D | Option exercise · Stock Option (Right to Buy) | +1,354 | 0 | ||
| 2022-08-11 | KURIYEL RALF Senior VP, R&D | Option exercise · Stock Option (Right to Buy) | +646 | 400 | ||
| 2022-08-04 | Gebski Christine See Remarks | Sale | −3,357 | $243.01 | $816K | 30,735 |
| 2022-08-03 | Bylund James Chief Operating Officer | Option exercise | +2,000 | $94.33 | $189K | 11,733 |
| 2022-08-03 | Bylund James Chief Operating Officer | Sale | −2,000 | $240.40 | $481K | 9,733 |
| 2022-08-03 | Bylund James Chief Operating Officer | Option exercise · Stock Option (Right to Buy) | −2,000 | 8,000 | ||
| 2022-08-01 | Snodgres Jon Chief Financial Officer | Sale | −2,000 | $220.00 | $440K | 37,187 |
| 2022-07-21 | Hunt Anthony Chief Executive Officer | Option exercise | +5,000 | $33.87 | $169K | 204,315 |
| 2022-07-21 | Hunt Anthony Chief Executive Officer | Option exercise | +15,154 | $32.40 | $491K | 219,469 |
| 2022-07-21 | Hunt Anthony Chief Executive Officer | Sale | −24,802 | $200.00 | $5.0M | 194,667 |
| 2022-07-21 | Hunt Anthony Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | +5,000 | 69,246 | ||
| 2022-07-21 | Hunt Anthony Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | +15,154 | 0 | ||
| 2022-05-26 | Mhatre Rohin Director | Grant or award | +1,202 | 1,659 | ||
| 2022-05-26 | Mhatre Rohin Director | Grant or award · Stock Option (Right to Buy) | +2,920 | 2,920 | ||
| 2022-05-26 | Konstantinov Konstantin Director | Grant or award | +534 | 534 | ||
| 2022-05-26 | Konstantinov Konstantin Director | Grant or award · Stock Option (Right to Buy) | +1,298 | 1,298 |
Page 19 of 23 · 455 trades